NR1H4 and metabolic dysfunction-associated steatohepatitis: It has been reported that Gypenosides can ameliorate HFD-induced non-alcoholic steatohepatitis (NASH) through direct activation of FXR and FXR-dependent signaling pathways [37], and significantly decreasing serum total cholesterol and LDL-C levels [38].